These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20018553)

  • 1. Metal complexes in medicine with a focus on enzyme inhibition.
    Che CM; Siu FM
    Curr Opin Chem Biol; 2010 Apr; 14(2):255-61. PubMed ID: 20018553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copper, gold and silver compounds as potential new anti-tumor metallodrugs.
    Tan SJ; Yan YK; Lee PP; Lim KH
    Future Med Chem; 2010 Oct; 2(10):1591-608. PubMed ID: 21426151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Molecular Receptors for the Specific-Target Delivery of Ruthenium and Gold Complexes into Cancer Cells.
    Machado JF; Correia JDG; Morais TS
    Molecules; 2021 May; 26(11):. PubMed ID: 34070457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cysteine proteases as targets for metal-based drugs.
    Fricker SP
    Metallomics; 2010 Jun; 2(6):366-77. PubMed ID: 21072382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non platinum metal complexes as anti-cancer drugs.
    Ott I; Gust R
    Arch Pharm (Weinheim); 2007 Mar; 340(3):117-26. PubMed ID: 17315259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New platinum and ruthenium complexes--the latest class of potential chemotherapeutic drugs--a review of recent developments in the field.
    Amin A; Buratovich MA
    Mini Rev Med Chem; 2009 Nov; 9(13):1489-503. PubMed ID: 20205631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor Activity of Pt(II), Ru(III) and Cu(II) Complexes.
    Gałczyńska K; Drulis-Kawa Z; Arabski M
    Molecules; 2020 Jul; 25(15):. PubMed ID: 32751963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Midas touch in cancer chemotherapy: from platinum- to gold-dithiocarbamato complexes.
    Ronconi L; Fregona D
    Dalton Trans; 2009 Dec; (48):10670-80. PubMed ID: 20023894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ruthenium(II) and Platinum(II) Complexes with Biologically Active Aminoflavone Ligands Exhibit In Vitro Anticancer Activity.
    Fabijańska M; Kasprzak MM; Ochocki J
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential new inorganic antitumour agents from combining the anticancer traditional Chinese medicine (TCM) liriodenine with metal ions, and DNA binding studies.
    Chen ZF; Liu YC; Liu LM; Wang HS; Qin SH; Wang BL; Bian HD; Yang B; Fun HK; Liu HG; Liang H; Orvig C
    Dalton Trans; 2009 Jan; (2):262-72. PubMed ID: 19089006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents.
    Peacock AF; Sadler PJ
    Chem Asian J; 2008 Nov; 3(11):1890-9. PubMed ID: 18712745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs.
    Ang WH; De Luca A; Chapuis-Bernasconi C; Juillerat-Jeanneret L; Lo Bello M; Dyson PJ
    ChemMedChem; 2007 Dec; 2(12):1799-806. PubMed ID: 17918761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
    Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
    J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent researches in metal supramolecular complexes as anticancer agents.
    Zhou CH; Zhang YY; Yan CY; Wan K; Gan LL; Shi Y
    Anticancer Agents Med Chem; 2010 Jun; 10(5):371-95. PubMed ID: 20380632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds.
    Casini A; Gabbiani C; Sorrentino F; Rigobello MP; Bindoli A; Geldbach TJ; Marrone A; Re N; Hartinger CG; Dyson PJ; Messori L
    J Med Chem; 2008 Nov; 51(21):6773-81. PubMed ID: 18834187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme inhibition as a key target for the development of novel metal-based anti-cancer therapeutics.
    Griffith D; Parker JP; Marmion CJ
    Anticancer Agents Med Chem; 2010 Jun; 10(5):354-70. PubMed ID: 20380633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action.
    Casini A; Hartinger C; Gabbiani C; Mini E; Dyson PJ; Keppler BK; Messori L
    J Inorg Biochem; 2008 Mar; 102(3):564-75. PubMed ID: 18177942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Application of metal ions and their complexes in medicine II. Application of platina complexes in the treatment of tumor].
    Nagy L; Csintalan G; Kálmán E; Nagy E; Sipos P
    Acta Pharm Hung; 2004; 74(4):213-22. PubMed ID: 16316049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pros and cons of bifunctional platinum(IV) antitumor prodrugs: two are (not always) better than one.
    Gabano E; Ravera M; Osella D
    Dalton Trans; 2014 Jul; 43(26):9813-20. PubMed ID: 24874896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.